S. aureus CRISPR/Cas9 monoclonal antibody (sample size)

10 μg
  Bulk order

Monoclonal antibody raised in mouse against the N-terminus of the S. aureus Cas9 nuclease (CRISPR-associated protein 9) using a recombinant protein.

Concentration2 μg/μl
Species reactivityMouse
PurityProtein G purified
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution References
Western Blotting 1:4,000 Fig 1
Immunoprecipitation 5 μg/IP Fig 2
Immunofluorescence 1:400 Fig 3
  • Validation data

    WB figure 1

    Figure 1. Western blot analysis using the Diagenode monoclonal antibody directed against S. aureus CRISPR/ Cas9
    Western blot was performed on protein extracts from HEK293 cells (lane 1), HEK293 cells transfected with S. aureus CRISPR/Cas9 (lane 2) and HeLa cells transfected with S. pyogenes Cas9 (lane 3) using the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230), diluited 1:4,000 in PBS-T containing 3% NFDM. The marker is shown on the left, position of the Cas9 protein is indicated on the right.

    IP figure 2

    Figure 2. IP using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
    IP was performed on whole cell extracts (200 μg) from HEK293 cells transfected with a Cas9 expression vector (lane 1, 3 and 5), or untransfected cells (lane 2, 4 and 6) using 5 μg of the Diagenode antibody against CRISPR/Cas9 (Cat. No. C15200230). The immunoprecipitated proteins were subsequently analysed by Western blot. The results obtained with the Cas9 antibody are shown in lane 3 and 4. The negative control (IP with beads only) is shown in lane 5 and 6, the input (10 μg) is shown in lane 1 and 2.

    IF figure 3

    Figure 3. Immunofluorescence using the Diagenode monoclonal antibody directed against S. aureus CRISPR/Cas9
    Transiently transfected U2OS cells expressing SaCas9-T2A-GFP were fixed with 3.7% formaldehyde, permeabilized in 0.5% Triton-X-100 and blocked in PBS containing 2% BSA for 2 hours at RT. The cells were stained with the S. aureus CRISPR/Cas9 antibody (cat. No. C15200230) diluted 1:400 in blocking solution at 4°C o/n, followed by incubation with an anti-mouse secondary antibody coupled to DyLight594 for 1 h at RT (left figure). Nuclei were counter-stained with Hoechst 33342 (right). The middle figure shows IF with an anti-GFP antibody.

  •  実験手法
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    Immunoprecipitation Read more
    Immunofluorescence: Diagenode offers huge selection of highly sensitive antibodies validated in IF. Immunofluorescence using the Diagenode monoclonal antibody directed against CRISPR/Cas9 HeLa cells transfected with a Cas9 expression vector (... Read more
  •  資料
    S. aureus CRISPR/Cas9 monoclonal antibody tds DATASHEET
    Datasheet of the S. aureus CRISPR/Cas9 monoclonal antibody
    Antibodies you can trust POSTER
    Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of lar...
    Epigenetic Antibodies Brochure BROCHURE
    More than in any other immuoprecipitation assays, quality antibodies are critical tools in many e...
  •  出版物

    How to properly cite this product in your work

    Diagenode strongly recommends using this: S. aureus CRISPR/Cas9 monoclonal antibody (sample size) (Diagenode Cat# C15200230-10 Lot# 001). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

    Life-Long AAV-Mediated CRISPR Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing Serious Lesions in mdx Mice.
    Xu L, Lau YS, Gao Y, Li H, Han R
    Previous studies from others and us have demonstrated that CRISPR genome editing could offer a promising therapeutic strategy to restore dystrophin expression and function in the skeletal muscle and heart of Duchenne muscular dystrophy (DMD) mouse models. However, the long-term efficacy and safety of CRISPR genome-e...

    Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy.
    Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA
    Duchenne muscular dystrophy (DMD) is a monogenic disorder and a candidate for therapeutic genome editing. There have been several recent reports of genome editing in preclinical models of Duchenne muscular dystrophy, however, the long-term persistence and safety of these genome editing approaches have not been addre...

    CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency.
    Matharu N, Rattanasopha S, Tamura S, Maliskova L, Wang Y, Bernard A, Hardin A, Eckalbar WL, Vaisse C, Ahituv N
    A wide range of human diseases result from haploinsufficiency, where the function of one of the two gene copies is lost. Here, we targeted the remaining functional copy of a haploinsufficient gene using CRISPR-mediated activation (CRISPRa) in and heterozygous mouse models to rescue their obesity phenotype. Transgeni...

  •  関連商品


  • ASHG
    Houston, TX
    Oct 15-Oct 19, 2019
  • ddd
    Oct 18-Oct 26, 2019
  • Neuroscience 2019
    Chicago, IL
    Oct 19-Oct 23, 2019

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics